CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Docetaxel +2 moredrug
Likely dose
Docetaxel 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01671332
NCT01671332Phase 2Completed
CompareCT.gov

Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

University of Wisconsin, Madison·interventional·Posted Aug 23, 2012·Updated May 12, 2020

In Brief

A Phase 2 clinical trial evaluating Docetaxel and Suramin for Carcinoma, Non Small Cell Lung. Completed, enrolled 80 participants across 2 sites.

Detailed Summary

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non Small Cell Lung
CountriesUnited States
CollaboratorsMedical College of Wisconsin, Optimum Therapeutics, LLC, Ohio State University

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2012
Enrollment StartJun 1, 2012
Primary CompletionJun 11, 2015
Study CompletionJun 16, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 13.9 years ago

Interventions

Docetaxeldrug

IV over 60 minutes, 75 mg/m2

Suramindrug

IV over 30 minutes

Docetaxeldrug

IV over 60 minutes. 56 mg/m2